SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- The global HPV testing and Pap test market size is expected to reach USD 7.3 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 16.4% from 2021 to 2028. The introduction of innovative tests, increasing awareness programs, rising public-private investments, and high incidence of HPV infections are some of the factors anticipated to foster market growth during the forecast period.
Key suggestions from the report:
- Based on test type, the Pap test segment accounted for the largest revenue share in 2020, owing to its widespread use in cervical cancer screening programs
- By application, the cervical cancer screening segment dominated the market in 2020, due to its higher incidence and mortality rates
- By product type, the consumables segment dominated the market in 2020, owing to its repetitive use to conduct testing in hospitals and laboratories
- The PCR segment is projected to show the fastest growth rate in the technology segment, owing to the enactment of new recommendations to use DNA HPV testing
- In Asia Pacific, the market is expected to witness lucrative growth as a result of the growing demand for HPV and Pap tests from emerging economies, such as China and India, which have a huge target population
Read 120 page research report with ToC on "HPV Testing And Pap Test Market Size, Share & Trends Analysis Report By Test Type, By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2021 - 2028'' at: https://www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Cervical cancer is a global problem, affecting millions of women. As per the Globocan estimates, in 2020, around 604,127 new cases of the cervix and uterine cancer were diagnosed globally, which led to around 341,831 deaths in the same year. According to the WHO, 99% of cervical cancer cases are linked with HPV infection. Such a high incidence and mortality rate of the disease has created a major demand for innovative and accurate screening for early detection and management. In addition, approval of novel testing solutions and services to upsurge screening rates is further anticipated to support market growth. In April 2020, Roche received FDA approval for its cobas HPV screening to be used on cobas 6800/8800 Systems, a fully automated and high-throughput system. Also, in February 2019, the Japanese company CMIC Healthcare Co., Ltd. launched SelCheck Cervical Cancer, a self-collect HPV test service focused on increasing the frequency of screening rates in the country.
The outbreak of novel corona virus (COVID-19) and nationwide lockdowns due to it in key geographies has drastically reduced the routine cervical cancer screening procedures. According to data published by the CDC, due to stay-at-home orders, the cervical cancer screening rate decreased by around 80% in California, U.S. Thus, such decreased testing rates have negatively affected the overall revenue growth of the market in 2020. However, increasing government initiatives to control the reducing testing rates is anticipated to offset the impact of COVID-19 in the near future. For instance, in February 2021, NHS England initiated a trial and offered at-home HPV testing kits to more than 31,000 women to carry out screening in the privacy and convenience of their own homes. This trial aims to increase the HPV screening rate in the country.
Grand View Research has segmented the global HPV testing and Pap test market on the basis of test type, application, product, technology, end-use, and region:
- HPV Testing & Pap Test Type Outlook (Revenue, USD Million, 2016 - 2028)
- HPV Testing
- Pap Test
- HPV Testing & Pap Test Application Outlook (Revenue, USD Million, 2016 - 2028)
- Cervical Cancer Screening
- Vaginal Cancer Screening
- HPV Testing & Pap Test Product Outlook (Revenue, USD Million, 2016 - 2028)
- Instruments
- Consumables
- Services
- HPV Testing & Pap Test Technology Outlook (Revenue, USD Million, 2016 - 2028)
- PCR
- Immunodiagnostics
- Other Technologies
- HPV Testing & Pap Test End-use Outlook (Revenue, USD Million, 2016 - 2028)
- Hospitals & Clinics
- Laboratories
- Others
- HPV Testing & Pap Test Regional Outlook (Revenue, USD Million, 2016 - 2028)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
List of Key Players of HPV Testing And Pap Test Market
- Abbott Laboratories
- Qiagen N.V.
- Becton, Dickinson and Company
- Quest Diagnostics, Inc.
- Hologic, Inc.
- F. Hoffmann-La Roche
- Femasys, Inc.
- Arbor Vita Corporation
- NURX, Inc.
- Seegene, Inc.
- Thermo Fisher Scientific, Inc.
- bioMérieux SA
Find more research reports on Clinical Diagnostics Industry, by Grand View Research:
- Cervical Cancer Diagnostic Market – The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is projected to grow at a CAGR of 5.9% over the forecast period.
- Rare Disease Genetic Testing Market – The global rare disease genetic testing market size was valued at USD 812.3 million in 2019 and is projected to register a Compound Annual Growth Rate (CAGR) of 10.9% from 2020 to 2027.
- Cholesterol Testing Products And Services Market – The global cholesterol testing products and services market size was valued at USD 14.8 billion in 2018 and is expected to witness lucrative CAGR of 7.9% over the forecast period.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
SOURCE Grand View Research, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=IO97706&Transmission_Id=202106020405PR_NEWS_USPR_____IO97706&DateId=20210602)
Share this article